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1. Introduction 
Coronary artery disease (CAD), also known as ischemic heart disease (IHD) and coronary 
heart disease (CHD), is caused by the narrowing (stenosis) of one or more coronary arteries, 
due to atherosclerosis, restricting blood flow and reducing the supply of oxygen to the heart 
muscle. Transient shortages in blood flow and oxygen lead to angina pectoris and chest 
pain, which may radiate to the left shoulder, arms, neck, back or jaw. Stable angina 
symptoms do not tend to progress in intensity over time. More seriously, the rupturing of 
an atherosclerotic plaque (causing a thrombotic occlusion) and stenosis of the vessel can 
result in acute myocardial infarction (AMI) due to a critical reduction in the blood supply to 
the heart muscle (myocardial ischemia). High levels of morbidity and mortality associated 
with this infarction are a consequence of ischemia. It is vital to promptly re-establish 
coronary blood flow after an infarction, because sustained ischemic damages and injuries to 
the heart muscle may lead to sudden death or heart failure. In addition to infarction, acute 
symptomatic manifestations of ischemic heart disease include unstable angina, and less 
common conditions such as cardiogenic shock and sudden death (Thygesen, 2007). 
Cardiovascular disease has a large budget impact, most of which is attributed to coronary 
artery disease. Therefore, effective treatment strategies are important to reduce associated 
costs. The total cost of coronary artery disease in the European Union (EU) is estimated to be 
over €49 billion and can be divided into direct health care costs (48%), productivity losses 
(34%) and informal care (18%) (Figure 1) (Allender, 2008). Estimated healthcare costs of 
ischemic heart disease in the EU approaches €24 billion, with approximately 50% of the 
economic burden due to in-patient care (€12.5 billion) and 25% associated with medication 
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(€6 billion). In 2006, mortality and morbidity associated with CAD were responsible for 
nearly €17 billion productivity losses across the EU, whilst informal care costs were 
estimated to be more than €9 billion (Allender, 2008). 
In 2010, ischemic heart disease was the main cause of death worldwide, causing 12.8% of 
world total deaths (WHO, 2011). Regarding Spain, three out of ten deaths are due to 
cardiovascular disease, being the leading cause of death even though its incidence has 
decreased almost a point with respect to the last known data, dating back to 2008 (INE 
2011). Specifically, cardiovascular disease has been responsible for 31.2% of the deaths 
caused in Spain during 2009, resulting in a total of 120,053 deceases. In conclusion, ischemic 
heart disease is one of the main causes of quality-adjusted life years lost (around 10% of 
disability), also producing 18% of the Spanish health expenditure, far above respiratory 
system diseases (13%), and poorly defined signs and symptoms (9%) (Gisbert y Brosa, 2005). 
Their direct health expenditure in Spain is nearly €727 million, with half of this cost being 
associated to hospitalizations caused by pathology, 43% to monitoring, and only 6% to 
pharmacological costs (MsyC, 2003).  
 
Source: Allender, 2008 
Fig. 1. Costs of Coronary Disease in EU (2006).  
2. Revascularization treatment of coronary artery disease: drug eluting stents 
Coronary revascularization in patients with atherosclerotic heart disease has emerged as the 
most accepted method of treatment in the last 50 years, still offering two types of 
procedures: surgical and percutaneous. 
The surgical technique for the implementation of vein and/or arterial grafts was developed 
in 1960. Since then, the procedure has not undergone many technical changes on the 
essentials, only an increase in the use of arterial grafts and the achievement of some 
procedures without extracorporeal circulation in minimally invasive surgery. However, 
despite the large experience learned over all these years, the results remain operator-
dependent and closely related to the amount of procedures performed by each surgeon. 
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Percutaneous Coronary Intervention (PCI) was first carried out in 1977. It was only reserved 
for patients with a disease in a single coronary artery, and supported by a surgical team. A 
clear difference between PCI and surgery is that Evidence-Based Medicine always 
accompanied interventional cardiology: advances have been supported by randomized 
multicenter studies before being implemented in all the centers. In the 1980's, PCI spread, 
but it was a very operator-dependent procedure, using rudimentary catheters and with a 
high number of complications (acute arterial occlusion in up to 15% of the procedures and 
restenosis in up to 40-50%). The PCI boom began in the 90's with the development and use 
of intracoronary stents and the remarkable improvement in balloon catheters, which solved 
early acute complications freeing the PCI from the surgical services and decreasing the 
restenosis rates. The BENESTENT study (Serruys et al., 1994) in Europe and the STRESS 
study (Fischman DL et al., 1994) in America, published in August 1994, gave rise to the 
spread of coronary stents. PCI stopped being operator-dependent when carried out in 
centers with a high overall volume, and the dreamt comparison with revascularization 
surgery began. Until then only the results with balloon catheters in general favored bypass 
surgery (GABI, EAST, RITA, ERACI, CABRI, BARI studies). Numerous comparative 
randomized studies were carried out between surgery and PCI in all kinds of situations and 
with different types of lesions (AWESOME, SoS, ERACI II, ARTS). The results were rather 
homogenous: there were not significant differences in terms of mortality, except in diabetic 
patients, between both techniques and differences only appeared in favor of surgery 
regarding the need of repeating bypass procedures in the short to medium term (Hoffman 
SN et al., 2003). 
Restenosis continued to be the Achilles' heel of PCI despite stents. All efforts were focused 
on the investigation of antiproliferative drugs linked to stents. In the year 2002, the results 
from the RAVEL study were published, showing a restenosis rate of 0% at 6 months after 
implantation of sirolimus-coated stents (Cypher®) (Morice MC et al., 2002). For several 
years, two kind of drug eluting stents (DES) coexisted largely; the above-mentioned 
sirolimus-coated stent and another stent coated with paclitaxel (TAXUS®). Many studies 
and registries were published on both DES in different clinical situations (SIRIUS program, 
TAXUS program, DIABETES I, ISAR program, COMPARE, etc...), all of them showing 
similar results in regard to decreased restenosis rates. The first study comparing the results 
of bypass surgery with PCI using sirolimus DES in patients with multivessel disease was the 
ARTS II study, which showed that there were not significant differences in the 
cardiovascular event rates between the group treated with DES and the comparative group 
treated with bypass surgery of the ARTS I study. However, the ARTS II study was widely 
criticized, because although the patients with multivessel disease included for DES 
treatment were more complex, the comparative surgical group was older. Two randomized 
multicenter studies were designed to compare the results of bypass surgery and PCI with 
DES in patients with multivessel disease, trying to clarify the controversies; one in diabetic 
patients, the FREEDOM study, and another one that included all kinds of coronary lesions, 
the SYNTAX study (Serruys PW et al., 2009). In the latter, 1800 patients with left main or 
three-vessel disease were randomized to bypass surgery or PCI with Taxus stent, provided 
that the surgery team and the interventionist cardiology team considered the patient a 
candidate for any of both interventions. At 12 months, the primary objective of non-
inferiority of PCI over surgery regarding MACCE (Major Adverse Cardiac and 
Cerebrovascular Events) was not achieved (17.8% vs. 12.4% for CABG; P=0.002), mostly due 
www.intechopen.com
Coronary Artery Disease 
 – Current Concepts in Epidemiology, Pathophysiology, Diagnostics and Treatment 
 
188 
to the increase in new bypass surgeries in the PCI group (13.5% vs. 5.9%, P<0.001). There 
were not significant differences in terms of mortality and Myocardial Infarctions (MI), but 
there was a higher number of strokes in the surgical group (2.2% vs. 0.6% with PCI; 
P=0.003). After a deep analysis of patients, the study showed that patients with a greater 
technical complexity derived from their anatomy (SYNTAX score higher than 32) may 
benefit more from surgery whereas patients with a low (0-22) or medium score (23-32) 
evolved similarly with both treatments. The analysis of the 705 patients with left main 
disease showed that those with isolated left main lesion or associated to one-vessel disease 
benefited more from PCI. 
Since 2005, new DES with different drugs (with or without polymers) were incorporated , all 
of them involving large study projects with a similar design to that applied to the projects of 
the first generation DES (SIRIUS, TAXUS projects). All the drugs used belong to the “limus” 
family, which present the lowest Late Loss Index; specifically, tacrolimus, zotarolimus, 
everolimus, and biolimus. Tacrolimus DES (JANUS®) failed to prove a lower restenosis rate 
than conventional bare metal stents (BMS). The zotarolimus DES (Endeavour®) was the first 
second generation stent available. The ENDEAVOR I, II, and III studies showed an excellent 
balance between the benefits of stent and restenosis reduction since the very beginning, 
helping the stent to position properly in the European market. Subsequently and with the 
same drug, the Resolute® stent and the third generation of DES, the Resolute Integrity®, 
were introduced, following the RESOLUTE FIM study. The Xcience V® and Prime® stents, 
using everolimus, were developed based on the SPIRIT investigation program, that includes 
the SPIRIT I, II, III, IV and V studies. As with the zotarolimus stent, we currently have a 
third generation of everolimus-coated stents already, Xcience Prime® and Promus 
Element®. Finally, a fifth drug, which is being used at the moment, is the biolimus 
(Biomatrix® and Nobori® stents) whose results come from randomized studies as 
LEADERS and NOBORI. 
Windecker et al., in The World Congress of Cardiology 2007, triggered an important 
controversy about the security of DES due to an increase in the occurrence of late subacute 
occlusions (Windecker S & Meier B, 2007). Kirtane et al., in an analysis of 34 observational 
studies between BMS and DES including 182,901 patients, showed a reduction in mortality 
(HR 0.78, 95% CI 0.71–0.86) and myocardial infarction rates (0.87, 95% CI 0.78–0.97) with the 
use of DES that remains similar after multivariate adjustment (Kirtane AJ et al., 2009). All 
the studies performed with second and third generation DES prove the results of this meta-
analysis with similar subacute occlusion rates to BMS.  
Recently, the European Society of Cardiology together with the European Society of Cardio-
Thoracic Surgery, have published new guidelines on myocardial revascularization (Task 
Force 2010). These guidelines state that, taking into account the anatomy, the 
revascularization has a recommendation of Class I1 in all cases with left main disease, two or 
                                                 
1 Classes of recommendations: Class I, Evidence and/or general agreement that a given treatment or 
procedure is beneficial, useful, effective; Class II, Conflicting evidence and/or a divergence of opinion 
about the usefulness/efficacy of the given treatment or procedure; Class IIa Weight of 
evidence/opinion is in favor of usefulness/efficacy; Class IIb, Usefulness/efficacy is less well 
established by evidence/opinion; Class III, Evidence or general agreement that given treatment or 
procedure is not useful/effective, and in some cases may be harmful. 
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three-vessel disease, proximal anterior descending artery lesion and one-vessel disease with 
more than 10% myocardial risk. In addition, according to the clinical practice, it is only 
contraindicated when the optimized medical treatment leaves the patient asymptomatic. 
Regarding the type of revascularization (surgery or PCI), guidelines suggest an 
individualized assessment by the cardiology and surgery team of each centre, assuming the 
general indications. Patients with Syntax high risk score (>33) and two or three-vessel 
disease have indication Class I for surgery and Class III for PCI. Patients with medium score 
(23-32) and impossibility of full revascularization by PCI have Class I indication for surgery 
and Class III for PCI. The rest of cases have both indications.   
2.1 Stent thrombosis 
Thrombosis of a coronary stent is a serious complication, which appears in almost 50% of 
the cases as transmural acute myocardial infarction, presenting a high mortality rate 
(Moreno R, 2005). This complication usually takes place during the first weeks after the stent 
implantation, and especially in the first 24 hours. Chronologically, stent thrombosis is 
classified as acute (in the first 24 hours after the stent implantation), sub-acute (between 24 
hours and 30 days), late (more than 30 days), and as a concept introduced more recently, 
very late (more than 6-12 months).  
The variables associated with a higher incidence of thrombosis are the existence of a visible 
thrombus before stent implantation, the implantation of more than one stent, left ventricular 
dysfunction, a suboptimal result, a non-elective stent implantation, small vessels, a residual 
dissection and a slow flow. 
2.1.1 Current recommendations in antiplatelet post-stent treatment 
In the initial years of using stents, anticoagulants were initially administered (heparin 
sodium at first and oral anticoagulation later for several months) in conjunction with 
acetylsalicylic acid (ASA). In this way, thrombosis rate was reduced to 3-4%. However, this 
reduction in stent thrombosis rate was at the expense of a high incidence of hemorrhagic 
complications. In subsequent years, several randomized studies showed that if 
anticoagulation was replaced with ticlopidine (antiplatelet drug from the group of 
thienopyridines which works by inhibiting adenosine-deaminase) the incidence of 
hemorrhagic complications and stent thrombosis decreased (Hall P et al., 1996; Urban P et 
al., 1998; Schömig A et al., 1996; Leon MB et al., 1998; Bertrand ME et al., 1998). With the 
appearance of clopidogrel (thienopyridine) the secondary effects associated to ticlopidine 
disappeared, becoming the drug of choice together with ASA after stent implantation. 
According to the Guidelines of the European Society of Cardiology, the double antiplatelet 
therapy in addition to ASA is recommended during 12 months after stent implantation in 
patients who suffer acute coronary syndrome, and during 6 months in patients with stable 
angina (Task Force 2010). Nevertheless, the risk of stent thrombosis with the higher assessed 
DES is being shown in long-term studies, despite serious doubts. On this point, the new DES 
is expected to offer advantages, although it will be necessary to get more evidence to 
eliminate uncertainty. For the second and third generation of DES, the stent thrombosis 
results are excellent, but the specific time of dual antiplatelet treatment with these devices is 
unknown and additional studies will be welcome. 
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3. Efficacy and effectiveness of RESOLUTE
® 
DES: preliminary results of 
REDES registry 
Drug Eluting Stents (DES) reduce the risk of restenosis, repeat interventions and re-
hospitalization compared to BMS due to the release of potent antiprofilerative drugs from 
the stent surface. However, despite the success of DES in reducing repeat revascularization 
procedures, about 5% of patients require repeat procedures within a year. In patients with 
diabetes or coronary heart disease in small vessels, these rates are higher (Stone GW et al., 
2004; Mauri L et al., 2010; Stolk JM et al., 2010). The incidence of myocardial infarction and 
death attributable to restenosis is minimal, but often causes recurrent angina. 
DES have also shown to significantly reduce stent thrombosis, which can be an important 
clinical problem resulting in an acute myocardial infarction (60-70%), death (20-25%) or 
emergency bypass surgery (Ayyanatahn S et al., 2009). Nevertheless, the occurrence of late 
stent thrombosis, between 30 days and a year after stent implantation, is one of the most 
complex effects of stent placement in general, and of DES in particular. 
Due to the above two points, the long-term safety of DES remains an important area of 
clinical research, especially in avoiding late stent thrombosis (Mauri L et al., 2007). 
Therefore, clinical studies with different DES are being conducted in order to demonstrate 
its effectiveness and long-term safety. To date, more than 100 DES randomized clinical trials 
in 60,000 patients have been performed, but quality varies considerably between different 
clinical trials, especially regarding the statistical powering and the selection of angiographic 
criteria instead of primary clinical endpoints. Accordingly, only a small proportion of DES 
can be recommended based on data from published studies as shown in Table 1 (Task Force 
2010). 
3.1 RESOLUTE
®
 clinical evidence 
The coronary stent Endeavor RESOLUTE® is a second generation stent indicated for 
improving coronary luminal diameter and reducing restenosis in patients with symptomatic 
ischemic heart disease in de novo arterial lesions of native coronary arteries with a reference 
vessel diameter of 2.25 to 4.0 mm and a lesion length ≤27mm. Its current clinical program 
consists of four clinical trials and two multicenter registries: RESOLUTE FIRST, RESOLUTE 
All Comers, RESOLUTE International, RESOLUTE US, RESOLUTE Japan, and RESOLUTE 
Asia. 
RESOLUTE FIRST is a prospective, multicenter, non-randomized, single arm study of the 
use of the Endeavor RESOLUTE® stent in patients with symptomatic ischemic heart disease, 
whose objective was to assess the safety and efficacy in the medium and long term. 139 
patients with 140 lesions were included in 12 centers of Australia and New Zealand, and 24-
month data are available. The results showed that the cumulative MACE rate at 12 months 
was 8.5%, and 11% at 24 months. The Target Lesion Revascularization (TLR) rate at one year 
was 0.8%, and at 12 months there were no Target Vessel Revascularizations (TVR). At two-
year follow-up, results showed a TLR, TVR, and Target Vessel failure (TVF) rates of 1.4%, 
0% and 7.9% respectively. One possible stent thrombosis occurred in the first year after 
implantation, however no late or very late thrombosis have occurred (Meredith IT et al., 
2009; Meredith IT et al., 2010). 
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DES Eluted drug Trials and references 
Clinical primary endpoint reached 
BioMatrix Flex Biolimus A9 LEADERS (Windecker el al., 
2008) 
Cypher Sirolimus SIRIUS (Moses et al., 2003) 
Endeavor Zotarolimus Endeavor II, III and IV 
(Fajadet et al., 2006; Gershlic 
el al., 2007) 
Resolute Zotarolimus RESOLUTE-AC (Serruys et 
al., 2007)  
Taxus Liberté/Element Paclitaxel TAXUS IV and V (Stone et 
al., 2004; Stone et al., 2005) 
PRESEUS-WH (Kerelakes et 
al., 2010) 
Xcience V Everolimus* SPIRIT III and IV (Stone et 
al., 2009; Stone et al., 2010) 
Angiographic primary endpoint reached 
Nevo Sirolimus NEVO RES I (Ormiston et 
al., 2010) 
Nobori Biolimus A9 NOBORI I Phase 1 and 2 
(Chevalier et al., 2007; 
Chevalier et al., 2009) 
Yubon Sirolimus ISAR-Test (Mehilli et al., 
2006) 
Selection is based on adequately powered RCT with a primary clinical or angiographic endpoint. With 
the exception of LEADERS and RESOLUTE (all-comers trial), efficacy was investigated in selected de 
novo lesions of native coronary arteries. 
*Promus Element device elutes everolimus from a different stent platform. 
DES = Drug Eluting Stent 
Table 1. Recommended drug-eluting stents (Task Force 2010). 
The randomized clinical trial, called RESOLUTE “All Comers”, collected data on more than 
15 centers in Western Europe and compared the zotarolimus eluting stent Endeavor 
RESOLUTE® with the everolimus eluting stent Xcience V (Serruys PW et al., 2010). Between 
April 2008 and October 2008 data from 1,292 patients with coronary artery disease and 
chronic stable and acute coronary syndromes were collected: 1,140 patients with 1,661 
lesions were assigned to the zotarolimus eluting stent Endeavor RESOLUTE ®and 1,152 
patients with 1,705 lesions to the everolimus eluting stent Xcience V. At thirteen month 
follow-up the Endeavor RESOLUTE ® stent was non inferior to the Xcience V stent with 
respect to the primary end point of TLF, which occurred in 8.2% and 8.3% of patients 
respectively (P>0.0001 for non-inferiority). There were no significant differences between 
the two patient groups in the rate of death from cardiac causes, any myocardial infarction, 
or revascularization. The rate of stent thrombosis (definitive, probable and possible) was 
2.3% in the Endeavor RESOLUTE® DES group and 1.5% in the Xcience V stent (p = 0.17). 
The lack of strict exclusion criteria in this study allows that the results are representative of 
actual clinical practice. 
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Yeung et al., in April 2011 published the 12-month follow-up data from the RESOLUTE US 
study (Yeung AC et al., 2011): a prospective, multicenter, observational study designed to 
assess the effectiveness of Endeavor RESOLUTE® DES in patients with one lesion who 
received a stent between 2.5 and 3.5 mm. Between August 2008 and December 2009 1,402 
patients from 116 centers in U.S. were included, with an average vessel diameter of 
2.59±0.47 mm and a diabetes prevalence of 34.4%. The results showed that the overall TLF 
rate at 12 months was 4.7% and cardiac death, myocardial infarction and TLR rates were 
0.7%, 1.4% y 2.8% respectively. 0.1% of patients presented stent thrombosis. 
Therefore, currently there are published data from three Endeavor RESOLUTE® studies, 
which have shown to reach a low rate of restenosis revascularization and clinical events 
such as death, myocardial infarction and stent thrombosis at one-year and two-year follow-
up (Table 2). Endeavor RESOLUTE® is an effective and safe stent for the treatment of 
patients with coronary artery disease in de novo lesions of native coronary arteries. 
 
 RESOLUTE FIRST 
(12 months) 
RESOLUTE All Comers 
(12 months) 
RESOLUTE US 
(12 months) 
 Endeavor 
RESOLUTE (1 
lesion) 
Endeavor 
RESOLUTE 
Xcience 
V 
Endeavor 
RESOLUTE ( 1 or 
2 lesions) 
 N=130 N=1,119 N=1,126 N=1,376 
MACE 8.5% 8.7% 9.7% 4.9% 
Death 2.3% 1.6% 2.8% 1.3% 
Cardiac death 0.8% 1.3% 1.7% 0.7% 
MI 5.4% 4.2% 4,1% 1.4% 
Q-wave MI 0.0% 0.7% 0.4% 0.1% 
Non-Q-wave MI 5.4% 3.6% 3.6% 1.2% 
TLR 0.8% 8.8% 8.2% 7.4% 
TVR (non-TL) 0.0% 4.9% 4.8% 4.6% 
TVR (TL) 0.8% 3.9% 3.4% 2.8% 
TLF 6.2% 8.2% 8.3% 4.7% 
TVF 6.9% 9.0% 9.6% 6.7% 
Stent Thrombosis 
(according to ARC, 
definitive, probable) 
0.0% 1.6% 0.7% 0.1% 
MI: Myocardial Infarction; TLR: Target Lesion Revascularization; TVR: Target Vessel Revascularization: 
TVF: Target Vessel Failure*; TLF = Target Lesion Failure** ARC = Academic Research Consortium 
criteria. 
*Defined as death from cardiac causes, any myocardial infarction (not clearly attributable to a non-
target vessel), or clinically indicated target-vessel revascularization) 
** Defined as death from cardiac causes, any myocardial infarction (not clearly attributable to a non-
target vessel), or clinically indicated target-lesion revascularization) 
Table 2. Summary of published clinical results (Endeavor RESOLUTE®).  
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3.2 REDES registry 
Recently was completed the follow-up of a prospective, multicenter, observational, one-arm 
registry, called REDES, whose objective was to assess the effectiveness and the resource use 
associated to the Endeavor RESOLUTE® DES in patients with de novo lesions in the native 
coronary arteries in the Spanish clinical practice. The primary endpoint was defined as the 
rate of Major Adverse Cardiac Events (MACE) at 30 days, 6 months and 12 months, 
including cardiac death, myocardial infarction (with or without Q wave), emergency bypass 
artery coronary graft (CABG) and TLV (repeat CABG or PTCA). Among the secondary 
endpoints were collected stent thrombosis rates, procedural success, device success, lesion 
success, TLR, and the identification and quantification of heath resources used in the 
management of patients at one year after stent implantation.  
The Inclusion criteria of patients were patients >18 years, signed informed consent form, drug 
eluting indication and the decision to use Endeavor Resolute® in all lesions. The exclusion 
criteria were pregnant or lactating women; patients with hypersensitivity or allergies to 
aspirin, heparin, clopidogrel, ticlopidine, zotarolimus, rapamycin, tacrolimus, sirolimus, 
cobalt, nickel, molybdenum or contrast media; patients who have contraindications for 
antiplatelet therapy and/or anticoagulants; patients with lesions not allowing the full inflation 
of angioplasty balloon; patients with other DES different from Endeavor Resolute® in other 
previous lesions; patients with a current medical condition associated with a life expectancy of 
less than 12 months; and patients who are participating in another study or have completed 
another study in the last 30 days before registry inclusion. Also, no restriction was placed on 
the total number of treated lesions, treated vessels or number of stent implanted. 
This study allows to know the clinical data and resource use in actual clinical practice with 
the Endeavor Resolute® stent. The lack of data on resource use and costs associated with 
treatment of coronary artery disease with DES, as well as their possible alternatives, make 
more relevant the studies which collect the actual resource use in routine clinical practice 
and allow to know the associated costs. These studies are the first step to know if stents are 
an effective and efficient treatment, and help make decisions within the National Health 
System. During the last years the inclusion of this information in protocols and data 
collection forms has been increasing in different studies. 
3.2.1 Clinical results 
Between January 2009 and February 2010 450 patients with 744 lesions from six Spanish 
hospitals were included. After reviewing the selection criteria, two patients were excluded, 
leaving 448 evaluable patients with 742 lesions. The exclusions were due to a myocardial 
infarction within 24 hours before the primary angioplasty procedure that led into a 
cardiogenic shock and death before obtaining the signed informed consent, and one patient 
whose clinical history showed a previous DES with another drug. 
The mean age of patients was 64.5 years and 78.3% were male, 34.1% had diabetes, 63.4% 
hypertension, 59.8% hyperlipidemia, and 28.6% smoked at the time of surgery. In addition 
to clinical risk, 31.9% of patients had a previous myocardial infarction, 20.1% a previous PCI 
and 4.5% a previous CABG. Most patients had lesions in 1 (55.6%) or 2 (29.9%) vessels, and 
left anterior descending artery was the most frequently treated. Also, it should be noted that 
14.2% of lesions had moderate to severe calcification, 18.9% presented a tortuosity greater 
than 45 °, and 11.9% bifurcation (Table 3).  
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Characteristic All valuable patients (n=448) 
Age, yrs 64.5 ± 10.9 
Male 78.3% 
Prior MI 31.9% 
          Q-wave MI 21.9% 
          Non-Q-wave MI 10.0% 
Prior PCI  20.1% 
Prior CABG 4.5% 
Diabetes Mellitus 34.1% 
          IDDM 8.9% 
Hyperlipidemia 59.8% 
Hypertension 63.4% 
History of smoking  
          Current 28.6% 
          Ex-smoker 28.3% 
Family history of cardiovascular disease 13.4% 
Worst status  
           Silent  ischemia 6.9% 
           Stable angina 28.3% 
           Unstable angina 31.0% 
           MI 33.9% 
Target lesion coronary artery (% total lesions)  
           Left anterior descending 46.0% 
           Left circunflex 18.1% 
           Right 27.0% 
           Left main 1.3% 
           Other 7.6% 
Number of treated vessels   
          1 55.6% 
          2 29.9% 
          3 8.9% 
          4 4.5% 
          5 1.1% 
TIMI flow grade 3 83.2% 
Thrombus 6.7% 
RVD, mm 2.89±0.46 
Lesion length, mm 18.08±10.36 
Minimum lumen diameter, mm 0.73±0.87 
%diameter stenosis 83.22±12.58 
Type B2/C lesion 48.6% 
CABG= coronary artery bypass grafting; IDDM= insulin-dependent diabetes mellitus; MI= myocardial 
infarction; MLD= minimum lumen diameter; PCI= percutaneous coronary intervention; RVD=reference 
vessel diameter; TIMI=thrombolysis in myocardial infarction 
Table 3. Baseline clinical, lesion and procedural characteristics. 
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The mean vessel diameter was 2.89 ± 0.46mm and the average lesion length 18.08 ± 
10.36mm. The Endeavor Resolute® stent was implanted in 95.5% of lesions treated, with a 
lesion success of 99.7%, a device success of 95.3%, and a procedure success of 94.7%. 
Preliminary results showed that the MACE rate was 1.3%, 3.6% and 4.8% at 30 days, 6 
months and 12 months respectively; and the rate of definite, probable and possible stent 
thrombosis according to the Academic Research Consortium criteria, was 0.7% and 1.4% at 
30 days and one year follow-up (Table 4). The 21 MACE, which occurred in 20 patients were 
6 cardiac deaths, 4 myocardial infarctions, 11 not programmed revascularizations in the 
same vessel or lesion treated during the intervention. 5 patients died from probable or 
possible stent thrombosis, one from a possible heart failure or ventricular arrhythmia not 
related to the stent, and the remaining non-cardiac death was due to a metastatic renal 
tumor that was detected a month after the inclusion of the patient in the study. Half of the 
stent thrombosis occurred within 4 days after surgery and most of restenosis 
revascularizations were performed by PTCA and only one was performed by CAGB. 
During the one-year follow-up 13 scheduled PTCA were performed in different vessels than 
those previously treated. 
 
 30 days 6 months 12 months 
 N = 445 N = 443 N = 441 
MACE 1.3% 3.6% 4.8% 
Death 0.5% 1.6% 1.6% 
Cardiac death 0.5% 1.3% 1.3% 
MI 0.5% 0.7% 0.9% 
Q-wave MI 0.2% 0.2% 0.2% 
Non-Q-wave MI 0.2% 0.5% 0.7% 
TLR 0.5% 1.6% 2.5% 
Stent Thrombosis  
(according to ARC, 
definitive, probable) 
0.7% 0.7% 0.7% 
Definitive 0.5% 0.5% 0.5% 
Probable 0.2% 0.2% 0.2% 
Possible 0.0% 0.7% 0.7% 
MACE = Major Cardiac Adverse Event; MI = Myocardial infarction; TLR = Target Lesion 
Revascularization; ARC = Academic Research Consortium criteria 
Table 4. Clinical outcomes at 30 days, 6 months and 12 months. 
If we compare these results with those obtained in the previously published study 
RESOLUTE All Comers, the MACE and stent thrombosis rates are better. The 
revascularization rate was lower considering that the proportion of diabetic patients of the 
REDES study was higher (34.1% vs. 23.5%), but the percentage of lesions in small vessels 
was lower (39.9% vs. 67.8%). The lack of strict exclusion criteria in this study such as 
patients with MI, multivessel disease, small vessels, long lesions, bifurcation, or tortuosity 
make this study representative of routine clinical practice and show actual results of the 
Endeavor Resolute® stent effectiveness even in patients who had suffered an MI within 72 
hours prior to surgery. Therefore, the REDES study results are comparable to and even 
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better than those obtained in previously published studies showing that the Endeavor 
Resolute® stent is safe and effective, and considering that a large percentage of patients had 
a high level of complexity. 
3.2.2 Resource utilization and costs 
The importance of identifying the use of health resources and costs associated with a 
procedure has increased considerably in recent years; however, there are still few studies 
that include this part in their objectives. Therefore, the REDES registry, in addition to 
providing the clinical results of Endeavor RESOLUTE® stent, also included the objective of 
identifying and quantifying the resource use from patient hospitalization until one year 
after the surgery in order to know the average cost of the intervention with Endeavor 
Resolute stent in Spain and at one-year follow-up. 
To calculate the costs of the analysis, both the resource data of the REDES study and the e-
Salud database were used. The e-Salud database is a private database of health care costs in 
Spain that can be accessed to obtain the unavailable costs with their maximum and 
minimum limits.     
Table 5 shows the results in more detail. The average cost of the procedure was €7,076.96, 
but the costs of pre-hospitalization, testing and analysis, and medication before the 
procedure must be added to have a more realistic view of the patient's cost. These costs 
were €2,011.93, €1,003.36 and €112.96 respectively. Patients were hospitalized for 2.45 days 
before the procedure, which involves an additional cost to be taken into account. Only the 
direct healthcare costs were calculated for the analysis. 
 
Procedure % patients Time (hours) Cost/Hour Assumption Total Costs 
€2011 
Hemodynamist 100% 1.27 33.24  42.07 
Nursing 100% 1.73 15.10  26.16 
Catheterization lab. 100% 1.73 388.21 Yes 671.60 
Observation unit 100% 2.93 55.71  163.41 
  Days Cost/Day   
Post procedure no ICU 100% 1.90 820.15  1,557.92 
Post procedure ICU 100% 0.72 1,479.1  1,066.40 
  Number Unit Costs   
Standard balloons 100% 1.04 561.95  584.53 
Cutting balloons 100% 0.03 561.95  17.56 
Endeavor Resolute® 100% 1.95 1,495.33  2,910.55 
BMS 100% 0.05 841.42  39.44 
DES 100% 0.03 1,495.33  43.39 
Complications     117.36 
TOTAL     7,076.98 
Table 5. Procedure costs 
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Analysis and tests % patients Average use Unit Costs Total Costs 
Pre-procedure no ICU (days) 100% 2.45 820.15 2,011.93 
Cardiac stress tests 15.18% 1.03 149.13 23.30 
ECG 100.00% 3.07 20.73 63.57 
CK analysis 74.11% 2.52 3.51 6.54 
CK-MB analysis 68.08% 2.76 12.62 23.73 
Troponin analysis 81.92% 2.92 15.57 37.28 
Creatine analysis 88.17% 2.03 3.84 6.87 
Eco Doppler 31.25% 1.06 104.21 34.66 
IVUS 6.03% 1.04 77.98 4.87 
Angiographies 97.54% 1.06 622.10 645.70 
Contrast medium 100.00% 253.59 0.62 156.85 
TOTAL    1,003.36 
Table 6. Pre-hospitalization, Analysis and tests costs (pre-procedure). 
The average one-year follow-up cost per patient was €1,502.29, including drug treatment 
and diagnostic tests, emergency room visits and hospitalizations for different causes. 
Hospitalizations are a key point in calculating annual costs and cost-effectiveness analysis. 
In spite of the stents effectiveness in the treatment of coronary artery stenosis, these patients 
have many comorbidities and frequently visit the hospital. Although the drug treatment has 
the smallest weight on the total cost, it is also interesting to look at the evolution of drug 
treatment in the patients. At first, nearly 100% of the patients had antiplatelet therapy, and 
at one-year follow-up only 25% had al least one antiplatelet drug. 
In conclusion, the total annual cost of a patient with coronary artery stenosis who is treated 
with Endeavor RESOLUTE® stent is €11,707.5 in Spain, where the cost of the procedure 
represents over 60%. The cost is similar to or slightly lower than that referred by other 
previously published studies on DES (Moreu et al., 2009). The higher initial cost of DES may 
be largely offset in the long term by reducing the number of hospitalizations and 
revascularizations, especially compared to other treatment alternatives, as it can be observed 
in several published cost-effectiveness analysis discussed below. 
4. Economic evaluation studies on Drug Eluting Stents 
Despite DES are more efficient reducing restenosis incidence, they have higher costs than 
conventional stents. This has opened a discussion around the use of DES. The arguments 
against have often focused on concerns that higher acquisition costs lead to a significant and 
unacceptable increase of healthcare costs. The arguments in favor are focused on the 
potential of DES to compensate their higher acquisition cost with the reduction of the 
number of repeat revascularizations and the costs associated with them (Macaya, 2004; 
Valdés, 2004).  
Therefore, from this discussion several studies have come up comparing costs and cost-
effectiveness of different alternatives (Table 9). The TAXUS I-IV series of clinical trials 
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30 day follow-up 
  % patients Average use Unit costs Total costs 
Emergency room 7.21% 1.00 126.21 9.10 
Blood transfusion 0.45% 2.50 132.62 1.49 
No. hospitalizations 2.70% 1.00     
ICU   3.92 1479.10 156.57 
no ICU  4.58 723.83 89.66 
Hemodynamist  1.33 33.24 1.20 
Nursing  1.50 15.10 0.61 
TOTAL (per patient) 258.63 
6 month follow-up 
  % patients Average use Unit costs  Total costs 
Emergency room 10.25% 1.24 126.21 16.10 
Blood transfusion 0.23% 1.00 132.62 0.30 
No. hospitalizations 8.66% 1.13     
ICU   0.61 1479.10 87.69 
no ICU  5.32 723.83 376.88 
Hemodynamist  1.41 33.24 4.59 
Nursing  1.55 15.10 2.29 
TOTAL  (per patient) 487.85 
12 month follow-up
  % patients Average use Unit costs Total costs 
Emergency room 12.44% 1.20 126.21 18.90 
Blood transfusion 0.46% 3.00 132.62 1.83 
No. hospitalizations 6.98% 1.06     
ICU   0.29 1479.10 31.92 
no ICU  5.81 723.83 312.38 
Hemodynamist  1.06 33.24 2.61 
Nursing  1.11 15.10 1.25 
TOTAL (per patient) 368.88 
Table 7. Emergency room and hospitalization costs.  
 
 Pre-procedure Discharge 30 days 6 months 12 months 
Aspirin 96.65% 99.11% 68.69% 65.60% 25.35% 
Clopidogrel 83.48% 99.55% 68.47% 64.92% 15.67% 
Ticlopidine 0.22% 0.00% 0.00% 0.00% 0.00% 
Table 8. Antiplatelet treatment. 
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evaluated the efficiency of the Taxus DES for percutaneous coronary intervention. Thus, the 
TAXUS-IV study, the first randomized trial of this series that incorporated a big pre-
specified cohort of patients managed in accordance with routine clinical practice without the 
need of angiographic follow-up, demonstrated that the use of paclitaxel-eluting stents 
increases hospitalization costs in $2,028 at first, although it was partially offset at one year 
by a reduction in the follow-up cost of $1,456 on the DES arm (Bakhai A et al., 2006). In this 
way, the average cost at one year was $14,583 for DES versus $14,011 for BMS (p-
value<0.001). Then, the cost-effectiveness ratio for paclitaxel-eluting stents was $4,678 for 
avoided revascularization and $47,798 for Quality Adjusted Life Year (QALY) gained 
(Bakhai A et al., 2006).  
 
Study 
Type of 
evaluation and 
synthesis 
Interventions Study population Country 
Period 
of study 
AETMIS, 
2004 
Cost-utility 
analysis 
DES (sirolimus 
and paclitaxel 
coated) versus 
BMS 
Régie de l’Assurance Maladie du 
Québec (RAMQ) database, 
unselected patients. Repeat 
revascularisation risk with DES 
taken from meta-analysis of 
published trials 
Canada 
6-13 
months 
Bagust et al., 
2006 
Cost-utility 
analysis 
DES (sirolimus 
and paclitaxel 
coated) versus 
BMS 
Cardiothoracic Centre (CTC) 
Liverpool population, unselected 
patients. Subgroup characteristics 
determined from a meta-analysis of 
published trials and CTC database 
UK 1 year 
Bakhai A et 
al., 2006 
Cost-
effectiveness 
analysis and 
Cost-utility 
analysis 
DES (paclitaxel 
coated) versus 
BMS 
Patients undergoing percutaneous 
coronary revascularization: results 
from the TAXUS-IV Trial USA 1 year 
Bischof M et 
al., 2009 
Cost-utility 
analysis 
DES (sirolimus 
and paclitaxel 
coated) versus 
BMS 
unselected patients with 
symptomatic ischaemic coronary 
artery disease 
USA 1+ year 
Brophy JM et 
al., 2005 
Cost-
effectiveness 
analysis 
DES 
(sirolimus) 
versus BMS 
Hypothetical cohort of patients 
undergoing PCI Canada 
9 
months 
Brunner et 
al., 2007 
Cost-
effectiveness 
analysis and 
Cost-utility 
analysis 
DES (sirolimus 
and paclitaxel 
coated) versus 
BMS 
826 patients included in the 
BASKET study- ‘real-world setting’
Switzerland 
18 
months 
Cohen, 2004 
Cost-
effectiveness 
analysis and 
Cost-utility 
analysis 
DES 
(sirolimus) 
versus BMS 
1,058 patients with plannned PCI of 
a single complex coronary artery 
stenosis (single native coronary 
artery). The lesion was de novo, 15-
30 mm in length with a reference 
vessel diameter of 2.5-3.5 mm. 
SIRIUS trial 
USA 1 year 
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Eisenstein 
EL et al., 
2009 
Cost-utility 
analysis 
DES 
(zotarolimus) 
versus BMS 
1,197 patients included in the 
ENDEAVOR II study USA 4 years 
Ekman M, 
2006 
Cost-
effectiveness 
analysis 
DES (paclitaxel 
coated) versus 
BMS 
Unselected patients 
Sweden 
1 year 
& 2 
years 
Greenberg, 
2004 
Cost-
effectiveness 
analysis 
DES 
(sirolimus) 
versus BMS 
Unselected patients 
USA 2 years 
Goeree R et 
al., 2009 
Cost-
effectiveness 
analysis and 
Cost-utility 
analysis 
DES (sirolimus 
and paclitaxel 
coated) versus 
BMS 
All stent procedures in the province 
of Ontario between December 1, 
2003, and March 31, 2005, with a 
minimum subject follow-up of 1 
year. 
Canada 2 years 
Gulizia et al., 
2004 
Cost-
effectiveness 
analysis 
DES 
(sirolimus) 
versus BMS 
Data obtained from literature and 
adapted to Sicilian population, 
using data form a survey 
conducted in seven local 
catheterisation laboratories 
Italy 1 year 
Kaiser et al., 
2005 
Cost-
effectiveness 
analysis 
DES (sirolimus 
and paclitaxel 
coated) versus 
BMS 
836 patients included in the 
BASKET study- ‘real-world setting’
Switzerland 
6 
months 
Lord SJ et al., 
2005 
Cost-
effectiveness 
analysis and 
Cost-utility 
analysis 
DES (sirolimus 
and paclitaxel 
coated) versus 
BMS 
Unselected patients 
Australia 1 year 
Mittman et 
al., 2005 
Cost-
effectiveness 
analysis 
DES (sirolimus 
and paclitaxel 
coated) versus 
BMS 
Patients treated in the trials 
(SIRIUS, TAXUS) and Babapulle 
meta-analysis 
Canada 1 year 
Moreu et al., 
2009 
Cost-
effectiveness 
analysis 
DES 
(zotarolimus) 
versus BMS 
Unselected patients, based on 
Endeavour trials Spain 5 years 
Shrive et al., 
2005 
Cost-utility 
analysis 
DES 
(sirolimus) 
versus BMS 
Unselected patients, based on 
Canadian database of 7,334 patients 
undergoing PCI between 1998 and 
2000 
Canada 
Patients
’ 
lifetime 
Tarricone et 
al., 2004 
Cost-
effectiveness 
analysis 
DES 
(sirolimus) 
versus BMS 
Patients suffering from stable or 
unstable angina, with de novo 
lesion(s). Case mix derived from 
unselected population of 1,809 
patients 
Italy 1 year 
Van Hout et 
al., 2005 
Cost-
effectiveness 
analysis 
DES 
(sirolimus) 
versus BMS 
238 patients with stable or unstable 
angina with planned PCI for single 
de novo coronary lesions. SIRIUS 
trial 
The 
Netherlands 
1 year 
Table 9. DES Economic Evaluations 
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Although the TAXUS-IV study was carried out in U.S., it can be extrapolated to the Spanish 
level, because in demographic terms its inclusion criteria make this study representative of 
the conditions in Spain (Stone et al., 2004; Stone, 2004). In Spain, the average age of patients 
with a percutaneous coronary intervention is 63 years old, as opposed to 62.5 years old from 
TAXUS-IV study. The male proportion in the Spanish population with coronary disease is 
74%, whereas in the TAXUS-IV study it was 72%. The proportion of diabetic people in the 
Spanish population who suffer from heart disease is nearly 25%, as opposed to 24.2% in the 
TAXUS-IV study. 
Since the TAXUS clinical trials were not performed in Spain, the data from the mentioned 
TAXUS-IV study were used to estimate the economic impact of the implantation of this stent 
in a Spanish hospital (Russel et al., 2006). The relevant cost data related to hospitalized 
patients that were considered for this estimation were collected from the Spanish costs 
database. The cost of a percutaneous coronary intervention was calculated based on the cost 
of Taxus versus BMS and multiplying by 1.54, assuming a standard mean of 1.54 stents per 
intervention. For the number of revascularization patients treated, a mean of 370 patients 
was assumed given the big difference in the number of patients treated in the Spanish 
hospitals. Some hospitals treat less than 200 patients per year, whereas other hospitals treat 
more than 1,000 (López-Palop et al., 2004). 
The analysis showed an expected cost at 12 months of €6,934 per patient for Taxus group 
and €6,756 for BMS group, i.e. 2.6% more than the Taxus group. Although the the cost for 
the Taxus group is higher due to higher costs of materials, 84% of this difference was 
compensated later with a lower probability of repeat revascularization. The cost for each 
repeat revascularization avoided with Taxus was estimated at €1,568. At 24 months, the cost 
difference decreased to 1.8% and the low probability of repeat revascularization 
compensated 91% of the increment in the initial cost of the procedure. 
It is important to emphasize that this cost difference requires a specific analysis in the case of 
high risk revascularization patients. These patients include those who have small vessels, 
suffer long lesions and, specially, diabetic patients, who, as said, represent the 25% of the 
population with coronary disease. In their case, at 12 months the BMS cost is already 3% 
higher than the Taxus cost, and the percentage increases to 4.5% at 24 months.  
The budget impact analysis was carried out considering two different settings. In the first 
setting, 90% of all patients of percutaneous coronary intervention receive Taxus instead of 
conventional stents, and 20% of patients who receive coronary surgery become Taxus 
patients. In this setting, the budget impact is 0.5% higher than in the base setting, although 
due to the reduction of surgery and reintervention, the capacity to treat patients in the 
surgery room increases in 8.5% with the same fixed costs and the same infrastructure. 
The second setting considers the treatment of 90% of the high-risk patients, while those not 
included in this group are treated with conventional stents. In this case, the savings 
compared to the base setting is nearly 1% and the increment of the surgery room capacity 
was 5% (Russell et al., 2006). 
The Cypher sirolimus-eluting stent was assessed after the SIRIUS clinical trial, which was 
carried out in 2004 in U.S. (Cohen et al., 2004). The patient characteristics were very similar 
to TAXUS-IV study, being the average age 62 years, 72.6% the average of male patients and 
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25% the proportion of diabetic patients. The economic analysis could be extrapolated to the 
Spanish market too, although this study has not been carried out yet in Spain. 
The cost difference in initial treatment was $ 2,856 higher in the case of the Cypher stent. 
However, follow-up and reintervention costs were significantly lower in this case, becoming 
$ 2,571 lower than with conventional stents. The total costs at one year for Cypher were $ 
309 higher than conventional stents (Cohen et al., 2004).  
The cost-effectiveness study concluded that the cost-utility per QALY was $ 27,540, within 
the acceptable thresholds from the hospital perspective. In addition, in some cases of the 
study where the lesion was longer than 25 mm, 3 stents were used instead of two long 
lengths. This would have reduced the number of stents by intervention from 1.4 to 1.3, 
therefore, the costs per patient would have decreased about $ 136. This study, compared 
with the previous one showed no significant differences in the costs for treating high-risk 
patients (Cohen et al., 2004). The analysis indicated that DES was economically dominant in 
patients with long lesions in small vessels. 
The Taxus stent has also been studied in Sweden by a decision model based on the 
revascularization rate, the resource use with its Swedish unit costs and the utilities based on 
the literature (Ekman M, 2006). From the public financing perspective, the average cost per 
patient treated at one year was €7,913 and €7,328 for Taxus stents and conventional stents 
respectively (Ekman M, 2006). The cost per repeat revascularization avoided was € 5,126 at 
one year and € 3,900 at 2 years. The results were more favorable in high risk patients: 
€47,791 per QALY and €838 per repeat revascularization avoided at 12 months. The budget 
impact was assessed too with 2 hypothetical scenarios and a baseline scenario. In the first 
scenario, 80% of high-risk patients were treated with DES instead of conventional stents, 
and the budget impact analysis increased 0.8%. In the second scenario, in addition to 80% of 
high-risk patients treated with DES instead of conventional stents, 20% of surgery patients 
with multivessel disease were treated with DES, and the budget impact analysis decreased 
0.8%(Ekman M, 2006). 
On the other hand, from the RAVEL study, Randomized Study with the sirolimus-eluting 
Bx Velocity balloon expandable stent in the Treatment of Patients with de novo native 
coronary artery lesions, it was demonstrated that the sirolimus DES generated an increase in 
the cost of the procedure of €1,284 per patient, although the net cost per year only resulted 
in an increase of €54 per patient (Van Hout et al., 2005). 
After the TAXUS-IV, SIRIUS and RAVEL studies, it was necessary to carry out a study that 
compared Taxus and Cypher with each other and included an evaluation against 
conventional stents. This study was conducted in Switzerland in the state of Basel, and was 
named BASKET (Basel Kosten Effektivitäts Trial). 
The BASKET study (Kaiser et al. 2005; Pfisterer et al., 2009) included more than 850 patients 
randomized into 3 similarly sized groups: those who received an uncoated stent, those who 
received Taxus and those who received Cypher. Thus, the study was planned and carried 
out in order to compare the increased cost-effectiveness of the three alternatives in patients 
with percutaneous coronary intervention. 
At six months it was observed that the use of DES reduced the adverse cardiac events rate 
in a 44%, especially in terms of revascularization, myocardial infarction or acute coronary 
www.intechopen.com
 
Effectiveness and Efficiency of Drug Eluting Stents 
 
203 
syndrome. There were not significant differences in efficacy between the two DES (Kaiser 
et al., 2005). This behavior continued for three years (Pfisterer et al., 2009), time in which 
the BASKET study was reevaluated. After these years it was also observed that these 
differences were more pronounced in patients who received long stents, while those who 
received shorter stents had fewer differences in effectiveness between DES and uncoated 
stents. 
Regarding the compared cost of the three options, at six months the initial higher cost of 
Taxus and Cypher could not be compensated, with a cost €1,702 higher than in the case of 
the conventional stents. After six months, due to the reduction of adverse events, this cost 
was finally €902 higher (Kaiser et al., 2005). The cost-effectiveness in preventing adverse 
cardiac events was €18,311 higher for DES, although this was reduced significantly in the 
subgroups of high risk patients such as diabetics, people over 65 years old, patients with 
more than a treated segment, and so on. The cost-utility ratio between DES versus standard 
stents was €73,283 per QALY using EQ-5D index, and €54,546 by visual analogue scale 
(Kaiser et al., 2005). 
Also, at 18 months, a higher total cost was observed in patients with DES compared to BMS 
(€11,808 [SD 400] per patient with DES and €10,450 [SD 592] per patient with BMS, mean 
difference of €1,358 [SD717], p <0.0001), due to the high cost of the stent shown in the study 
(Brunner-La Rocca et al., 2007). Therefore, the calculation of cost-effectiveness ratio was 
€64,732 per major adverse cardiac events avoided, and €40,467 per QALY gained. The stent 
cost, the number of events, and QALYs were the main causes for not reaching an acceptable 
cost-effectiveness ratio. 
In patients at low risk, the probability that DES reached an Incremental Cost-Effectiveness of 
€10,000 or less to prevent major adverse cardiac events was 0.016, but was 0.874 in patients 
at high risk. In this way, it denotes the major differences between Incremental Cost-
Effectiveness of patients at low risk and high risk. When the cost-utility ratio is assessed, a 
similar pattern can be observed, being low-risk patients 41% less effective and more 
expensive with a probability of being cost-effective of 0.11 (threshold below €40,000 per 
QALY) whereas in the case of high-risk patients 76% of patients were more effective and 
cheaper than BSM, being the probability of cost-effectiveness of 0.975. 
In the study of Shrive FM et al. (2005), it was estimated a cost per QALY of 58,721 Canadian 
dollars using the sirolimus DES compared to conventional stents. In diabetic patients and 
patients older than 70 years old the use of DES is more cost-effective. In this way, other 
short-term Canadian study (9 months) found that the cost per repeat revascularization 
avoided was 23,067 Canadian dollars and that the most cost-effective strategy was the use of 
DES in high-risk populations (7,800 Canadian dollars) (Brophy et al., 2005). Delimiting the 
vision to a hospital perspective, the cost-effectiveness ratio for avoided revascularization 
showed values in a range from 12,527 to 29,048 Canadian dollars (AETMIS, 2004). 
Many other economic evaluation studies have focused on the comparison of DES vs. BMS 
combining various types of DES. Thus in Australia, from a National Health System 
perspective, the incremental cost per repeat revascularization avoided was 3,750 
Australian dollars with sirolimus and 6,100 Australian dollars with paclitaxel at 12 
months (Lord SJ et al., 2005). On the other hand, the cost per QALY was 46,829 Australian 
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dollars and 76,467 Australian dollars with sirolimus and paclitaxel respectively. The 
authors concluded that limiting DES to patients at high risk may improve the cost-
effectiveness (Lord SJ et al. 2005). 
In UK, where a treatment is considered cost-effective below €42,000 or with a neutral cost at 
12-month follow-up from a public financing perspective, DES were not cost-effective in 
comparison to BMS except  for a selected group of patients  (Bagust et al., 2006). In the same 
way, a Swiss study of Kaiser et al. showed a higher cost per patient for DES compared to 
BMS with an average of €10,544 against €9,639 from a health system financing perspective. 
Thus, the average cost difference between the 2 types of stents was €1,702 per patient, 
showing a cost per cardiac event avoided of €18,311 and a cost per QALY of €50,000 (Kaiser 
et al., 2005). Again, the subgroup analysis showed that DES were more cost-effective in 
high-risk patients (older than 65 with multivessel disease). 
The latest studies, which assessed both Taxus and Cypher, indicated that in patients not 
selected previously DES are not cost-effective and they are becoming more cost-effective in 
high-risk patients (Bischof M et al., 2009 , Goeree R et al., 2009). In this way, the Bischof 
study, based on 17 randomized trials, showed that the cost of BMS was $25,460, the cost of 
sirolimus was $28,250 and $29,299 for paclitaxel (Bischof M et al., 2009). It all means that the 
probability of being cost-effective in the United States (threshold of $100,000 per QALY) was 
8.3% and 2.8% for sirolimus and paclitaxel, respectively (Bischof M et al., 2009). For the 
Ontario study the differences in the revascularization rate were observed mainly in patients 
with two or more risk factors. Therefore, the cost per repeat revascularization and the cost 
per QALY were above the threshold (Goeree R et al., 2009). 
The latest alternative of DES on the market was Endeavor, a zotarolimus coronary stent. 
Endeavor has demonstrated its effectiveness and safety with the Endeavor-I study and its 
benefits in the Endeavor-II study (Fajadet et al., 2007). The latter showed that Endeavor 
reduces the probability of suffering an adverse cardiac event from 14.4% to 7.3% and the 
restenosis rate was 35% for BMS and 13.2% for Endeavor. 
With clinical data from the Endeavor II study (Randomized Controlled Trial to Evaluate the 
Safety and Efficacy of the Medtronic AVE ABT-578 Eluting Driver Coronary Stent in De 
Novo Native Coronary Artery Lesions), Endeavor clinical and economic benefits were 
assessed in U.S compared to BMS (Eisenstein EL et al., 2009). The clinical data, the resource 
use and the follow-up of 1,197 patients were used (598 Endeavor vs. 599 BMS), applying the 
quality of life of secondary sources over 4 years of follow-up. 
The use of Endeavor versus BMS at 4 years reduced the target vessel revascularization rate 
(10.4 vs. 21.5, P <0.001), but the analysis showed no significant differences regarding 
mortality or non-fatal myocardial infarction. Applying a discount of 3% no difference in 
QALYs was observed (1.093 vs. 1.090; p = 0.69), or the total health costs ($ 21,483 vs. $ 
21,680, P = 0.78) (Eisenstein EL et al., 2009). 
Using the data from the ENDEAVOR-II, Moreu et al. performed a Markov model with 
monthly cycles to compare the efficacy data of Endeavor with other therapeutic alternatives 
and draw an economic of the Spanish market. Data on resource use associated with the 
different options and the unit costs were obtained from local data and were validated by 
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experts. These costs were expressed in 2007 Euros with a time horizon of 5 years (Moreu et 
al., 2009). 
This analysis showed that the cost per restenosis avoided by Endeavor was €6,851 at 1 year 
and €10,831 at 5 years, and costs for adverse cardiac event avoided were €7,003 and € 11,322 
respectively. In this way, the lower incidence of complications with Endeavor compared to 
BMS resulted in an improvement of quality-adjusted survival of patients, which was 
progressive and strongly associated with the simulation period of the analysis, being almost 
0 at 1 year. Thus, an increment of QALYs is perceived over time, since the values of cost per 
QALY gained is €132,877, €34,229 and €10,505 to 1, 2 and 5 years respectively (Moreu et al. 
2009), 
This study also included a comparison with other alternatives such as surgery, and showed 
that Endeavor is a less expensive option, with savings decreasing over the period of 
analysis. 
Therefore, this study coincided with the cost-effectiveness analysis of the BASKET study, in 
which the higher costs of DES compared to conventional stents were mainly due to the 
higher initial cost of the procedure. The results at 2 years showed that these short-term 
higher costs are partially offset by further reductions in the incidence of complications and 
revascularization need. In addition, cost-effectiveness ratios also decrease with time (Moreu 
et al. 2009; Kaiser et al., 2005). 
5. Discussion 
The risk of repeat revascularizations using BMS is between 5% and 14% in the published 
registries, which is much lower than that observed in clinical trials (over 30%). Therefore, 
the absolute reduction of repeat revascularization with DES compared to BMS, or the 
marginal improvement of DES, is very limited in actual life. This leads to a higher cost 
combination for DES compared to BMS and low improvements in the quality of live by a 
low latitude, which make it more difficult to obtain favorable cost-effectiveness ratios to 
DES in all the countries. 
In the recent years, there has been a growing interest in economic evaluation of health 
technologies, with a progressive increment of the number of articles in medical journals. 
Nevertheless, this increment does not translate into an increment in the quality of the 
studies, and the lack of methodological strength has been the general trend. This is because 
economic evaluation is relatively a new field (its use in the healthcare system began, with 
few exceptions, in the nineties when the health cost soared and new technologies with 
higher prices progressively appeared) which uses methods and concepts alien to medical 
knowledge and causes confusion in the terms use and the followed objectives.  
The economic evaluation try to determine which technology is more efficient or, which is 
the same, what technology produces better health outcomes depending on the resources 
invested, once the costs, risks and benefits are identified, measured and compared. 
The economic implications of the use of DES have lead to the proliferation of economic 
evaluation studies throughout the world. In short, in relation to the use of DES, it is widely 
www.intechopen.com
Coronary Artery Disease 
 – Current Concepts in Epidemiology, Pathophysiology, Diagnostics and Treatment 
 
206 
acknowledged that its cost is the true limiting factor; for example, in our area the price of 
DES is 60-80% higher than conventional stents. Although many studies concluded that DES 
may be cost effective in large subgroups of patients, under real conditions, the DES cost-
effectiveness do not come out favorably compared to BMS (Neyt M et al. 2009; Hill RA et al. 
2007; Kuukasjärvi P et al., 2007). 
In the current global economic crisis, the presentation of studies with data from the actual 
clinical practice which demonstrate a reduction in the final costs with the DES use in the 
national health system is crucial to decision making and efficiency. Therefore, the stents are 
still one of the crosshairs of Health Technology Assessment bodies. Since 2006, 8 HTA have 
been published with a moderate to high quality, which showed different conclusions based 
on the published clinical evidence, especially in terms of mortality. Five of them reviewed 
the published economic evidence and concluded that DES are more effective in high-risk 
patients, despite the great disparity between studies and the great variance in the results 
and cost-effectiveness ratios. 
In conclusion, in the last years a great effort has been made to improve the safety and 
efficacy of new coronary stents. However, studies with larger patient populations and a 
long-term follow-up are necessary to evaluate the effectiveness of the new stents and then 
show that DES are a cost-effective treatment, because they will remain an important part of 
treatment of PCI in the near future. 
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